StockNews.AI
HEPA
StockNews.AI
55 days

Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

1. Hepion Pharmaceuticals transitioned to OTCQB Venture Market as of June 25, 2025. 2. HEPA begins trading on the OTCQB under the same symbol HEPA. 3. The company specializes in diagnostic tests for multiple diseases. 4. This marks a significant step for Hepion's market presence.

2m saved
Insight
Article

FAQ

Why Bullish?

Transitioning to the OTCQB increases visibility and potential investor interest, historically leading to price gains.

How important is it?

The transition signifies increased credibility and access for investors, crucial for clinical-stage firms.

Why Short Term?

The immediate effects of improved trading visibility may be realized quickly.

Related Companies

HEPAMRNANVAXPHUNABUS
MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that it has successfully completed the process of transitioning to the OTCQB Venture Market. The Company’s common stock begins trading on the OTCQB Venture Market today, June 25, 2025 with the trading symbol, HEPA. About Hepion Pharmaceuticals Hepion is a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma. For further information, please contact: Hepion Pharmaceuticalsinfo@hepionpharma.com

Related News